Tokyo, Japan and Ghent, Belgium - October 1st, 2013 - Miraca Holdings Inc., a Japan-based holding company in the healthcare sector listed on the Tokyo Stock Exchange, today announced that its affiliate Innogenetics N.V. will change its name to Fujirebio Europe N.V. with immediate effect. The name change is the next logical step in an integration process that was launched by the acquisition in September 2010 of Innogenetics N.V. by Fujirebio Inc., a subsidiary of Miraca Holdings. Fujirebio was founded more than 60 years ago and is today a leading international healthcare company dedicated to conceiving, developing, producing and marketing high quality in vitro diagnostics (IVD) testing solutions worldwide.
"This is an important and symbolic new chapter in the already rich life of our company," said Takeshi Koyama, President and CEO of Fujirebio. "Our company is today internationally recognized as a key player in oncology for routine and novel IVD markers. Through the years we have also gained a strong reputation in infectious disease testing in Japan. This name change marks another big step towards becoming a truly international player serving and earning the trust of IVD customers and demonstrating our commitment to patient health across the world."
"After 25 years of delivering high quality pioneering testing solutions to the IVD market under the name of Innogenetics we are now all very excited about becoming Fujirebio Europe," said Christiaan de Wilde, CEO of Fujirebio Europe. "It goes without saying that our processes, our quality system and our constant focus on providing our customers with products and services of the highest quality remain the same."
The name change confirms Fujirebio's strong commitment to the introduction of the LUMIPULSE® immunoanalyzer range in laboratories across Europe. Fujirebio already has a long, successful history of providing reliable automated full routine immunoassay IVD testing solutions to the IVD market in Japan. The LUMIPULSE® G1200 was presented to the European market for the first time in Italy in November 2011 and this fully automated chemiluminescent enzyme immunoassay (CLEIA) system is now available to laboratories in Spain and will soon be available in Germany and France.
"Over the last 25 years we have gained a position as one of the world leaders in manual and semi-manual strip-based IVD testing solutions with strong brands such as INNO-LIATM and INNO-LIPA,” said Christiaan de Wilde. “These products lines, along with our INNOTEST® and INNO-BIA ranges, will obviously continue to be of high importance for us and for our customers."
In conjunction with the name change, Fujirebio Europe also launches a next generation website in order to provide customers and partners with all relevant information related to its activities and products. Customers may access a dedicated online eServices section containing regulated documentation, videos, privileged contact information and other added value services at a 24/7 basis. The new website can be found at www.fujirebio-europe.com.
Fujirebio is a leading international healthcare company with a strong focus on high quality in vitro diagnostics (IVD) testing solutions. Founded more than 60 years ago in Japan, the company is today recognized as the world-wide market leader in oncology for both routine and novel markers and has a strong reputation in Japan in infectious disease testing in clinical labs and blood banks. Over the last 20 years Fujirebio has been committed to bringing solid and successful automated immunoassay testing solutions and state of the art chemiluminescent assay products to the market. Under the name Innogenetics (now Fujirebio Europe) the company has also been pioneering the field of molecular diagnostics and multiparameter testing. The company is today one of the world leaders in strip-based diagnostics solutions.
The product lines range from specialized manual testing to fully automated routine testing and they cover disease fields such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone.
Fujirebio is a subsidiary of Japan-based Miraca Holdings (listed in the Tokyo Stock Exchange - MRCHF) and counts more than 1,100 employees working in Asia, Europe and America, including subsidiaries. For more information about Fujirebio please visit www.fujirebio.com/english or www.fujirebio-europe.com.
About Miraca Holdings
With group net sales of ¥192.2 billion (FYE 3/2013), Miraca Holdings, a Japan-based holding company in the healthcare sector listed on the Tokyo Stock Exchange, is engaged in the business consisting of three segments: (i) development, manufacture, and commercialization of in vitro diagnostics, (ii) clinical laboratory testing, and (iii) other healthcare related businesses, which are conducted by its subsidiaries and affiliates including Fujirebio Inc,. a leading supplier of in vitro diagnostics, and SRL, Inc., Japan’s largest commercial laboratory. For more information about Miraca Holdings, please visit www.miraca-holdings.co.jp/eng/index.html.